Table 2 Clinicopathological characteristics between patients with and without PNI
From: Nomogram predicts risk of perineural invasion based on serum biomarkers for pancreatic cancer
Variables | PNI-positive group | PNI-negative group | P value |
|---|---|---|---|
(n = 252) | (n = 137) | ||
Age ≤ 60 years, N (%) | 124 (49.2%) | 69 (50.4%) | 0.827 |
Male, N (%) | 144 (57.1%) | 83 (60.6%) | 0.511 |
BMI, mean (SD), kg/m2 | 23.1 (2.9) | 23.1 (2.9) | 1.000 |
ASA grade ≤ II, N (%) | 217 (86.1%) | 123 (89.8%) | 0.297 |
Biliary infection, N (%) | 8 (3.2%) | 4 (2.9%) | 1.000 |
Obstructive jaundice, N (%) | 149 (59.1%) | 48 (35.0%) | < 0.001 |
Weight-loss ≥ 5 kg, N (%) | 27 (10.7%) | 16 (11.7%) | 0.772 |
Preoperative Hb, median (IQR), g/L | 126.0 (117.0, 136.0) | 129.0 (119.0, 139.0) | 0.042 |
Preoperative BG, median (IQR), mmol/L | 5.8 (5.1, 7.3) | 5.2 (4.6, 6.1) | < 0.001 |
Preoperative ALB, median (IQR), g/L | 38.9 (35.5, 40.8) | 39.4 (37.0, 42.1) | 0.055 |
Preoperative TBIL, median (IQR), µmol/L | 85.8 (12.6, 210.3) | 14.0 (9.3, 67.2) | < 0.001 |
Preoperative CA19-9, median (IQR), U/mL | 189.5 (55.8, 569.2) | 42.3 (14.1, 206.6) | < 0.001 |
Preoperative CEA, median (IQR), ng/mL | 3.2 (2.1, 4.7) | 2.6 (1.7, 4.4) | 0.484 |
Preoperative CA125, median (IQR), U/mL | 14.0 (9.7, 21.5) | 11.7 (8.3, 17.0) | 0.012 |
Preoperative FIB, median (IQR), per g/L | 3.9 (3.2, 4.7) | 3.4 (2.9, 4.3) | 0.001 |
Maximum tumor size, median (IQR), cm †| 3.0 (2.5, 3.8) | 3.0 (2.5, 4.0) | 0.275 |
Median RFS (95% CI), months | 12.3 (11.3–13,3) | 22.7 (17.6–27.8) | < 0.001 |
Median OS (95% CI), months | 19.1 (16.7–21.5) | 29.4 (21.9–36.9) | < 0.001 |
Postoperative adjuvant therapy, N (%) | 171 (67.9%) | 108 (78.8%) | 0.356 |